Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
On a wing and a prayer Leap heads for phase 3.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Opdivo and Yervoy succeed again, but the US path remains unclear.
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
The company might need something better to replace its ageing blockbuster.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
